Human Papillomavirus: Screening, Testing, and Prevention

 

With more than 200 types identified, human papillomavirus (HPV) commonly causes infections of the skin and mucosa. HPV infection is the most common sexually transmitted infection in the United States. Although most HPV infections are transient and subclinical, some lead to clinical manifestations ranging from benign papillomas or warts to intraepithelial lesions. In some patients, persistent infection with high-risk mucosal types, especially HPV-16 and HPV-18, causes anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancers. Most HPV-related cancers are believed to be caused by sexual spread of the virus. A history of multiple sex partners; initiation of sexual activity at an early age; not using barrier protection; other sexually transmitted infections, including HIV; an immunocompromised state; alcohol use; and smoking have been identified as risk factors for persistent HPV infections. Screening for HPV infection is effective in identifying precancerous lesions and allows for interventions that can prevent the development of cancer. Use of condoms and dental dams may decrease spread of the virus. Vaccination is the primary method of prevention. The nonavalent HPV vaccine is effective in preventing the development of high-grade precancerous cervical lesions in noninfected patients. Vaccination is ideally administered at 11 or 12 years of age, irrespective of the patient's sex. In general, a two-dose series is recommended if administered before 15 years of age; however, individuals who are immunocompromised require three doses.

There are more than 200 types of human papillomavirus (HPV), a DNA virus that infects cutaneous and mucosal epithelial cells. HPV is spread by direct skin-to-skin contact and has tropisms for cutaneous or mucosal epithelial cells.1 A small subset of HPV types can cause cutaneous warts.2 The approximately 40 types that infect mucosal surfaces are typically spread through sexual contact, including vaginal, anal, or oral sex, and can be divided into low-risk and high-risk types based on their associated cancer risk. Low-risk types cause warts, whereas the 15 high-risk types cause cervical intraepithelial neoplasia (CIN) and squamous cell carcinomas of the anogenital tract and oropharyngeal mucosa.3,4 Vertical or horizontal spread of HPV can occur during the perinatal period and is associated with oral infections and respiratory papillomatosis.5,6 Concomitant cervical and anal infections have been demonstrated in women without a history of anal intercourse and may be a result of autoinoculation.7

WHAT'S NEW ON THIS TOPIC

Human Papillomavirus

Vaccination has been demonstrated to reduce the prevalence of vaccine-type HPV in females, anogenital warts, and precancerous cervical lesions.

According to a 2018 Cochrane review, vaccinating women, with or without HPV exposure, between 15 and 26 years of age decreases the risk of cervical intraepithelial neoplasia 2 and 3, with a number needed to treat of 39.

On June 12, 2020, the U.S. Food and Drug Administration approved adding the prevention of head and neck cancers caused by HPV as an indication for the nonavalent HPV vaccine (Gardasil 9).

HPV = human papillomavirus.

 Enlarge     Print

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingComments

Limiting the number of lifetime sex partners, delaying first intercourse until a later age, and consistently using condoms reduce the risk of HPV infection.13,14

C

Mixed-quality randomized controlled trials of disease-oriented outcomes

Smoking and alcohol cessation should be recommended to reduce the risk of HPV persistence and the development of HPV-related malignancies.15,16

C

Two case-control studies

Vaccination should be recommended to prevent the development of high-grade precancerous cervical lesions in women.57,63,64

C

Consistent findings from a Cochrane review of randomized controlled trials of disease-oriented outcomes; evidence-based practice guideline

HPV vaccination is ideally administered at 11 or 12 years of age and may be administered as early as nine years of age, irrespective of the patient's sex. In immunocompetent individuals immunized before 15 years of age, a two-dose series is indicated. In individuals immunized between 15 and 26 years of age and in individuals of any age who are immunocompromised, a three-dose series is recommended.57,62

C

Evidence-based practice guidelines

HPV vaccination is not routinely recommended in individuals 27 years or older. Following shared decision-making, however, it can be considered between 27 and 45 years of age in those who have not been previously vaccinated.57

C

Evidence-based practice guideline

In patients 21 to 29 years of age, cervical cancer screening should be performed every three years using cervical cytology alone. In patients 30 to 65 years of age, cervical cancer screening should be performed every three years using cervical cytology alone,

The Author

JEFFREY D. QUINLAN, MD, FAAFP, is a professor in and chair of the Department of Family Medicine at the University of Iowa Carver College of Medicine, Iowa City. At the time this article was written, he was a professor in and chair of the Department of Family Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Md.

Address correspondence to Jeffrey D. Quinlan, MD, FAAFP, Roy J. and Lucille Carver College of Medicine, University of Iowa, 01286D PFP, 200 Hawkins Dr. Iowa City, IA 52242 (email: jeffrey-quinlan@uiowa.edu). Reprints are not available from the author.

Author disclosure: No relevant financial affiliations.

References

show all references

1. McQuillan G, Kruszon-Moran D, Markowitz LE, et al. Prevalence of HPV in adults aged 18–69: United States, 2011–2014. NCHS Data Brief. 2017;(280):1–8....

2. Kilkenny M, Merlin K, Young R, et al. The prevalence of common skin conditions in Australian school students. Br J Dermatol. 1998;138(5):840–845.

3. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men. Sex Transm Dis. 2013;40(3):187–193.

4. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–527.

5. Chung CH, Bagheri A, D'Souza G. Epidemiology of oral human papillomavirus infection. Oral Oncol. 2014;50(5):364–369.

6. Sabeena S, Bhat P, Kamath V, et al. Possible non-sexual modes of transmission of human papilloma virus. J Obstet Gynaecol Res. 2017;43(3):429–435.

7. Hernandez BY, McDuffie K, Zhu X, et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev. 2005;14(11 pt 1):2550–2556.

8. Chesson HW, Dunne EF, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–664.

9. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer [published correction appears in N Engl J Med. 2008;359(15):1637]. N Engl J Med. 2007;357(16):1589–1597.

10. Han JJ, Beltran TH, Song JW, et al. Prevalence of genital human papillomavirus infection and human papillomavirus vaccination rates among US adult men: National Health and Nutrition Examination Survey (NHANES) 2013–2014. JAMA Oncol. 2017;3(6):810–816.

11. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26(suppl 10):K1–K16.

12. Gillison ML, Broutian T, Pickard RKL, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307(7):693–703.

13. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354(25):2645–2654.

14. Wen LM, Estcourt CS, Simpson JM, et al. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect. 1999;75(5):312–316.

15. Haukioja A, Asunta M, Söderling E, et al. Persistent oral human papillomavirus infection is associated with smoking and elevated salivary immunoglobulin G concentration. J Clin Virol. 2014;61(1):101–106.

16. Oh HY, Kim MK, Seo S, et al. Alcohol consumption and persistent infection of high-risk human papillomavirus. Epidemiol Infect. 2015;143(7):1442–1450.

17. Zoodsma M, Nolte IM, Schipper M, et al. Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study. J Med Genet. 2005;42(8):e49.

18. American Society of Clinical Oncology. Cervical cancer: risk factors. November 2020. Accessed March 12, 2021. https://www.cancer.net/cancer-types/cervical-cancer/risk-factors

19. American Cancer Society. Risk factors for cervical cancer. Updated January 3, 2020. Accessed March 12, 2021. https://www.cancer.org/cancer/cervical-cancer/causes-risks-prevention/risk-factors.html

20. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814.

21. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine. 2008;26(suppl 10):K17–K28.

22. Centers for Disease Control and Prevention. Cancers associated with human papillomavirus, United States—2012–2016. U.S. cancer statistics data briefs, no. 18. September 2020. Accessed March 12, 2021. https://www.cdc.gov/cancer/uscs/about/data-briefs/no18-hpv-assoc-cancers-UnitedStates-2013-2017.htm

23. Rübben A, Kalka K, Spelten B, et al. Clinical features and age distribution of patients with HPV 2/27/57-induced common warts. Arch Dermatol Res. 1997;289(6):337–340.

24. Silverberg MJ, Thorsen P, Lindeberg H, et al. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol. 2003;101(4):645–652.

25. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–428.

26. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(2):123–137.

27. Grabowski MK, Gray RH, Serwadda D, et al. High-risk human papillomavirus viral load and persistence among heterosexual HIV-negative and HIV-positive men. Sex Transm Infect. 2014;90(4):337–343.

28. Lacey CJN. Therapy for genital human papillomavirus-related disease. J Clin Virol. 2005;32(suppl 1):S82–S90.

29. Bruggink SC, Eekhof JAH, Egberts PF, et al. Natural course of cutaneous warts among primary schoolchildren: a prospective cohort study. Ann Fam Med. 2013;11(5):437–441.

30. Finley C, Korownyk C, Kolber MR. What works best for nongenital warts? Can Fam Physician. 2016;62(12):997.

31. Diaz ML. Human papilloma virus: prevention and treatment. Obstet Gynecol Clin North Am. 2008;35(2):199–217, vii–viii.

32. Snijders PJF, Steenbergen RDM, Heideman DAM, et al. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208(2):152–164.

33. Wang Z, Gu Y, Wang H, et al. Distribution of cervical lesions in high-risk HPV (hr-HPV) positive women with ASC-US: a retrospective single-center study in China. Virol J. 2020;17(1):185.

34. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia– grade 2. Obstet Gynecol. 2009;113(1):18–25.

35. Boda D, Docea AO, Calina D, et al. Human papilloma virus: apprehending the link with carcinogenesis and unveiling new research avenues (review). Int J Oncol. 2018;52(3):637–655.

36. McCredie MRE, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425–434.

37. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1274–1280.

38. Moore KA II, Mehta V. The growing epidemic of HPV-positive oropharyngeal carcinoma: a clinical review for primary care providers. J Am Board Fam Med. 2015;28(4):498–503.

39. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–172.

40. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321–346.

41. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening. J Low Genit Tract Dis. 2015;19(2):91–96.

42. Practice bulletin no. 168: cervical cancer screening and prevention. Obstet Gynecol. 2016;128(4):e111–e130.

43. U.S. Preventive Services Task Force. Cervical cancer: screening. August 21, 2018. Accessed January 24, 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening

44. Solomon D, Papillo J, Davis Davey D. Statement on HPV DNA test utilization. J Low Genit Tract Dis. 2009;13(3):135–136.

45. Stoler MH, Castle PE, Solomon D, et al.; American Society for Colposcopy and Cervical Pathology. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007;127(3):335–337.

46. Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2011;49(2):557–564.

47. Levi AW, Bernstein JI, Hui P, et al. A comparison of the Roche Cobas HPV test with the Hybrid Capture 2 test for the detection of high-risk human papillomavirus genotypes. Arch Pathol Lab Med. 2016;140(2):153–157.

48. Cuzick J, Cadman L, Mesher D, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108(4):908–913.

49. Boers A, Wang R, Slagter-Menkema L, et al. Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening. J Clin Microbiol. 2014;52(12):4391–4393.

50. U.S. Preventive Services Task Force. Oral cancer: screening. November 15, 2013. Accessed September 2, 2020. https://uspreventiveservicestaskforce.org/uspstf/recommendation/oral-cancer-screening

51. American Academy of Family Physicians. Clinical preventive service recommendation. Oral cancer. Accessed September 2, 2020. https://www.aafp.org/patient-care/clinical-recommendations/all/oral-cancer.html

52. American Dental Association. ADA expands policy on oral cancer detection to include oropharyngeal cancer. October 1, 2019. Accessed September 2, 2020. https://www.ada.org/en/publications/ada-news/2019-archive/september/ada-expands-policy-on-oral-cancer-detection-to-include-oropharyngeal-cancer

53. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35(9):1127–1134.

54. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in MMWR Recomm Rep. 2015;64(33):924]. MMWR Recomm Rep. 2015;64(RR-03):1–137.

55. Cranston RD, Hart SD, Gornbein JA, et al. The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men. Int J STD AIDS. 2007;18(2):77–80.

56. Committee on Adolescent Health Care. Committee opinion no. 582: addressing health risks of noncoital sexual activity. Obstet Gynecol. 2013;122(6):1378–1382.

57. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698–702.

58. Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years. Lancet. 2017;390(10108):2143–2159.

59. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208(3):385–393.

60. Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006–2014. Am J Public Health. 2018;108(1):112–119.

61. Gargano JW, Park IU, Griffin MR, et al. Trends in high-grade cervical lesions and cervical cancer screening in 5 states, 2008–2015. Clin Infect Dis. 2019;68(8):1282–1291.

62. Robinson CL, Bernstein H, Poehling K, et al. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger – United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(5):130–132.

63. Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;(5):CD009069.

64. Fogleman C, Leaman L. Prophylactic vaccination against human papillomavirus to prevent cervical cancer and its precursors. Am Fam Physician. 2019;99(1):15–16. Accessed January 25, 2021. https://www.aafp.org/afp/2019/0101/p15.html

65. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57(1):7–28.

66. American College of Obstetricians and Gynecologists. Human papillomavirus vaccination. Committee opinion no. 809. Accessed March 12, 2021. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/08/human-papillomavirus-vaccination

67. Kjaer SK, Nygård M, Sundström K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. EClinicalMedicine. 2020;23:100401.

68. Centers for Disease Control and Prevention. Human papillomavirus (HPV). November 15, 2019. Accessed March 12, 2021. https://www.cdc.gov/hpv/hcp/index.html

69. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine. Lancet. 2009;374(9706):1975–1985.

70. U.S. Food and Drug Administration. sBLA clinical review memorandum. Accessed March 12, 2021. https://www.fda.gov/media/139433/download

71. Juckett G, Hartman-Adams H. Human papillomavirus. Am Fam Physician. 2010;82(10):1209–1213. Accessed January 25, 2021. https://www.aafp.org/afp/2010/1115/p1209.html

 

 

Copyright © 2021 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

CME Quiz

More in Pubmed

MOST RECENT ISSUE


Oct 2021

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article